GlassScriptPhysician profile
Farah Mehdi
NPI 1033189477
$4,331.18
in general payments reported to CMS, 2019-2025
30 companies · $640 in 2025
The $640 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $956 · 2020: $444 · 2021: $670 · 2022: $701 · 2023: $563 · 2024: $357 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,559.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $484.43 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $467.80 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $419.33 | 2019-2025 | Rybelsus, Ozempic |
| Amgen INC. | $410.14 | 2019-2025 | Evenity, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $400.72 | 2019-2025 | Jardiance, Ofev, Spiriva Respimat |
| Lilly USA, LLC | $302.87 | 2019-2024 | Mounjaro |
| Pfizer INC. | $290.10 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $223.66 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $204.53 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $182.70 | 2019-2024 | Xarelto |
| Abbvie INC. | $156.23 | 2019-2025 | |
| Astellas Pharma US INC | $141.89 | 2019-2022 | |
| Exact Sciences Corporation | $95.95 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $79.07 | 2020-2023 | Verquvo, Belsomra |
| Amneal Pharmaceuticals LLC | $71.03 | 2022-2023 | Unithroid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $61.49 | 2020-2021 | |
| Allergan, INC. | $44.76 | 2020 | |
| Eisai INC. | $35.97 | 2021 | |
| Sumitomo Pharma America, INC. | $34.88 | 2025 | Gemtesa |
| Biogen, INC. | $29.98 | 2024 | Skyclarys |
| E.R. Squibb & Sons, L.L.C. | $29.58 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.56 | 2022-2023 | |
| Circassia INC. | $24.82 | 2019 | |
| Nevro Corp. | $19.85 | 2024 | Senza |
| Verona Pharma, INC. | $18.54 | 2025 | Ohtuvayre |
| Otsuka America Pharmaceutical, INC. | $18.04 | 2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $16.91 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.63 | 2022 | |
| Nalpropion Pharmaceuticals LLC | $11.38 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farah Mehdi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.